In a recent podcast episode, Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joined Julie Yoo, Daisy Wolf, and Will Shrank of a16z Bio + Health to discuss how payors and providers are approaching anti-obesity medications. They also delved into topics such as pricing and prior authorization considerations.
This episode is part of a series focusing on the science and supply of GLP-1s. In the previous episode, Brooke Boyarsky Pratt, founder and CEO of knownwell, shared insights on the significance of patient-centric medical homes. Prior to that, Carolyn Jasik, Chief Medical Officer at Omada Health, provided a clinical perspective on GLP-1s.
The conversation between Manolis and the a16z team sheds light on the evolving strategies and perspectives within the healthcare industry regarding anti-obesity medications. By bringing together experts in pharmacy, investing, and healthcare technology, the podcast episode offers a comprehensive look at this important topic. Listeners can gain valuable insights into how different stakeholders are addressing the challenges and opportunities in this space.
Barcelona's star midfielder Pedri will continue to be with his national team squad at Euro…
In seven weeks, Georgia Tech will kick off their season by traveling to Dublin to…
Jude Bellingham is already looking ahead to the Euro 2024 final on July 14. He…
Former Alabama Crimson Tide running back Josh Jacobs is embarking on a new chapter in…
Auburn is regaining momentum on the recruiting trail as July begins. Two days after tight…
Utah Utes fans had reason to celebrate during their season opener against Florida as Money…